Discover AstraZeneca's groundbreaking patent for dual-target antibody molecules aimed at EGFR and c-Met, paving the way for innovative cancer therapies.

Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging ...

The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, ...

Despite advancements in early detection and innovative treatments, Black women in the United States face higher mortality ...

The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.

Discover Lyell Immunopharma's groundbreaking patent for EGFR-derived polypeptides, enhancing cancer treatment through innovative nucleic acid technologies and engineered T cells.

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...